spk-9001
Pfizer and Spark Therapeutics granted FDA breakthrough designation for haemophilia drug
July 22, 2016Medical Communications, Research and Development FDA, Pfizer, Spark Therapeutics, haemophilia B, spk-9001
Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
